The foundational research here traces back to Loren Pickart, whose decades of work culminated in a widely cited 2018 review in the International Journal of Molecular Sciences documenting that GHK-Cu modulates the activity of thousands of human genes tied to tissue remodeling, antioxidant defense, and inflammatory regulation
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
Yeast Overgrowth: depression, memory impairment, behavioral disorders low energy levels, hyperactivity, weak immune system, dementia, and neurological conditions can be flared by yeast Fatty Acid Metabolism: elevated fatty acids & ketones may be an indicator of protein deficiency which can cause lethargy, confusion, irritability and exacerbate ADHD symptoms
These substances are prohibited in sports by the World Anti-Doping Agency
3321c4.jpg)
